IDegAsp treatment was associated with improved glycaemic control and reduced hypoglycaemia rates: a real-world study

Gregory R Fulcher; Shahid Akhtar; Saleh J Al-Jaser; Johan Medina; Mafauzy Mohamed; Nemencio A Nicodemus Jr; Anne Helene Olsen; Kiran P Singh; Adri Kok

Supplementary Figure 1: Patient flow through the study

- Patients invited for the study (n=1462)
- Signed informed consent (n=1122)
- Patients initiated on IDegAsp (n=1102)
  - Australia (n=183)
  - India (n=185)
  - Malaysia (n=182)
  - Philippines (n=185)
  - Saudi Arabia (n=188)
  - South Africa (n=179)
- Included in the FAS (n=1102)
- Completed treatment period (n=1015)
- Reasons for not completing the study (n=87)
  - Withdrawal of informed consent (n=8)
  - Lost to follow-up (n=43)
  - Death (n=7)
  - Other (n=29)

IDegAsp, insulin degludec/insulin aspart; FAS, full analysis set.